Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Infect Dis
Κύριοι συγγραφείς: Tapia, Milagritos D., Findlow, Helen, Idoko, Olubukola T., Preziosi, Marie-Pierre, Kulkarni, Prasad S., Enwere, Godwin C., Elie, Cheryl, Parulekar, Varsha, Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Akinsola, Adebayo K., Adegbola, Richard A., Kampmann, Beate, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, Viviani, Simonetta, Tang, Yuxiao, Plikaytis, Brian D., Marc LaForce, F., Carlone, George, Borrow, Ray
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2015
Θέματα:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639509/
https://ncbi.nlm.nih.gov/pubmed/26553683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ672
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια